Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus TECHNETIUM TC99M MERTIATIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus TECHNETIUM TC99M MERTIATIDE KIT.
MPI INDIUM DTPA IN 111 vs TECHNETIUM TC99M MERTIATIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Technetium Tc99m mertiatide is a radiopharmaceutical that undergoes renal tubular secretion and glomerular filtration, allowing imaging of the kidneys. After intravenous administration, it is primarily taken up by the kidneys and excreted into the urine, providing visualization of renal perfusion and function.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
1 mCi (37 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life: 1.5–2.1 hours (mean 1.8 h). Effective half-life with Tc-99m decay: physical half-life 6.02 h, biological half-life ~1.8 h, effective half-life ~1.4 h. Clinically, imaging completed within 30–60 min post-injection.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Renal: >90% of injected dose excreted via glomerular filtration and tubular secretion within 24 hours. Biliary/fecal: <1%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical